Lifetime Valve Management: The Gap Between Clinical Trials and Real Life
- maryrburrell
- 1 day ago
- 3 min read
Structural heart disease is not always a one valve problem.
In today’s world of rapid transcatheter innovation, new clinical trials for aortic, mitral, and tricuspid valve disease are changing lives. Patients who once had no options now have real hope through structural heart clinical trials and transcatheter therapies. Innovation is moving fast, and that is something to celebrate.
But here is the question we need to start asking: what happens when a patient who joined one heart valve clinical trial later needs treatment for another valve in a different trial with a different care team?
Because that happens.
Multiple valve disease is not rare. Heart valve disease is often progressive. Many patients with structural heart disease will face multi valve involvement over time. One valve is treated. Another begins to fail. A patient who built deep trust with one structural heart team may suddenly find themselves entering a new trial with a new sponsor, new coordinators, new physicians, and a new protocol.
Clinically, this may make sense. Emotionally, it can feel like the ground just shifted under your feet. Like you finally exhaled with one team, only to tighten back up and start proving yourself all over again. It can feel like being asked to hand your heart to strangers twice. To rebuild trust while short of breath. To explain your story again when you barely have the energy to live it.
Clinical trials are organized around one device. Patients live with hearts that change over years. The body does not stay in one box just because the system is built that way.
Right now, there is no universal standard that guarantees a lifetime valve plan when a patient moves from one clinical trial or program to another. Care can become split across teams, and it is not always clear who is accountable for the full picture. A simple written transition summary may not always exist. Communication between teams is not always structured or consistent. Conversations about how multiple valves will be treated over time are not always clearly documented.
So the patient becomes the one holding it all together.
They retell their story.
They gather their own records.
They try to connect the dots between teams.
They carry the stress of rebuilding trust while managing symptoms.
That is a heavy load for someone already living with heart valve disease.
The system is strong at running individual clinical trials. The next step in structural heart care is building stronger lifetime management across those trials.
If we want lasting innovation in heart valve treatment, we must build lasting trust that continues beyond one protocol.
That could look like this:
⚡️ A clear lifetime valve plan that follows the patient.
⚡️ One accountable valve lead who sees the full picture and helps coordinate care across teams and trials.
⚡️ Simple transition summaries when a trial ends.
⚡️ Clear sharing of imaging and medical records between programs.
⚡️ Structured communication for patients with more than one valve involved.
⚡️ Honest conversations about how valves may need to be treated over time.
This isn’t about criticizing innovation. It’s about what happens after the trial ends.
Patients are not chapters in a study. They are permanent stakeholders living with these decisions for the rest of their lives.
Whether you are a patient living with multi valve disease or a leader shaping structural heart innovation, this gap affects all of us.
Patients deserve continuity. Innovation deserves trust that survives beyond one trial.
If you are working in structural heart care or living with multi valve disease, this is the conversation we need to keep building together.
HeartBridge Collective is turning lived experience into action and helping shape lifetime valve management. We are working to move structural heart care beyond single procedures and toward lasting trust. Through practical tools and structured support, we connect patients, teams, and trials while strengthening continuity across a lifetime of valve care.
Bridging hearts, minds, and innovation — one lived experience at a time.